β2微球蛋白水平在成人急性髓性白血病中的临床意义

目的测定血清中岛微球蛋白在急性髓性白血病（AML，acute myeloid leukemia）患者血清的表达水平，探讨其临床意义。方法以淋巴瘤（1ymphoma）、多发性骨髓瘤（MM，multiple myeloma）患者作为阳性对照组，以正常人群为阴性对照，采用RIA法检测不同病情（包括完全缓解、初治或复发）急性髓性白血病患者＆微球蛋白的表达水平并收集相关临床及实验室检查资料，分析岛微球蛋白水平与临床多项指标的关系。结果在急性髓性白血病患者中：初治／复发组的＆微球蛋白水平（2396．84±1442：86）μg／L较阴性对照组（934，55±571．69）μg／L及完全缓解组（1279．11±462．92）μg／L显著升高（P〈0．01），与阳性对照中的初治／复发患者（淋巴瘤2491．93±1156．49μg／L，多发性骨髓瘤（7012．69±5305．64）μg／L比较无统计学意义（P〉0．05），其值的高低与外周血淋巴细胞、粒细胞、幼稚细胞计数呈正相关（P〈0．05）。结论岛微球蛋白水平是反映急性髓性白血病肿瘤负荷的一个有效指标，对判断病情、预后，提示复发有一定作用。

The clinical application of Beta- 2 - microglobulin in adult acute myeloid leukemia

Objective To determine the level of beta - 2 - microglobulin in adult patients with acute myeloid leukemia in different statuses of disease （untreated/relapse/refractory, partial remission, complete remission） and discuss its clinical implication of it. Methods The levles of beta - 2 - microglobulin in acute myeloid leukemia patients at remission stage, initial and recurrent stages were determined and anlayzed with the levels of lymphoma and multiple myeloma patients as opsitive control and that of normal population as negative control. In addition, clinical data were collected for analysis of its clinical significance. Results The levels of beta - 2 - microglobulin in the patients with acute myeloid leukemia in initial and recurrent groups were significantly elevated （2396.84 ± 1442.86μg/L） compared to complete remission group（ 1279.11 ± 462.92μg/L）and the negative normal group （934.55 ± 571.69μg/L） （P 〈 0.01 ） , there waa no significant difference compared with the positive control group（2491.93 ± 1156.49μg/L for lymphoma patients, 7012.69 ±5305.64μg/L for multiple myeloma, P 〉 0.05） ; The level was positively correlated with the counts of white blood cell , lymphocyte and eukemic cell （P 〈 0.05 ）. Conclusion The level of beta - 2 - microglobulin in patients with acute myeloid leukemia may be a useful indicator in reflecting tumor load.